Low-dose IL-2 increases the number of Tregs; it has clinically used for the treatment of lupus and lupus nephritis [56,57] and is currently being tested in AIH [58,59] and other autoimmune diseases [60,61]. The gene discussed is IL2; the disease is autoimmune hepatitis.